Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
July 24, 2023
Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023
June 22, 2023
Beyond Air® Secures up to $40 Million Debt Financing
June 15, 2023
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
June 15, 2023
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast
May 16, 2023
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting
April 19, 2023
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
March 23, 2023
Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting
March 14, 2023
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023
February 22, 2023
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023
February 9, 2023

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe